<DOC>
	<DOC>NCT01232491</DOC>
	<brief_summary>This trial is conducted in Europe, and North and South America. The aim of this trial is to investigate if a dietary intervention has an effect on weight when initiating insulin treatment in subjects with type 2 diabetes currently treated with oral antidiabetic drugs (OADs).</brief_summary>
	<brief_title>Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Body Weight Changes</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Type 2 diabetes (diagnosed clinically) for at least 6 months prior trial start Insulin naive subjects HbA1c: 7.09.0 % (both inclusive) Body Mass Index (BMI): 25.045.0 kg/m^2 (both inclusive) Use of Thiazolidinedione (TZDs) or Glucagonlike peptide1 analogue (GLP 1) receptor agonists within the last 3 months prior to trial enrollment Cardiovascular disease within the last 6 months Recurrent severe hypoglycaemia or hypoglycaemic unawareness or hospitalisation for diabetic ketoacidosis during the previous 6 months Uncontrolled treated/untreated severe hypertension, impaired liver function, impaired renal function, known proliferative retinopathy or maculopathy requiring treatment Cancer and medical history of cancer in the past 5 years (except basal cell skin cancer or squamous cell skin cancer) Pregnancy, breastfeeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>